Table 1.
Baseline features of study population.
| Crohn’s disease (118) | |
|---|---|
| Male gender, n (%) | 77 (65.3) |
| Age at enrollment (years), mean ± SD | 36.1 ± 15.1 |
| Disease duration (months), mean ± SD | 123.4 ± 104.5 |
| Age at diagnosis, n (%) | |
| A1 | 32 (27.1) |
| A2 | 67 (56.8) |
| A3 | 19 (16.1) |
| Disease location, n (%) | |
| L1 | 23 (19.5) |
| L2 | 8 (6.8) |
| L3 | 84 (71.2) |
| L4 | 3 (2.5) |
| Disease behavior, n (%) | |
| B1 | 46 (39) |
| B2 | 52 (44.1) |
| B3 | 20 (16.9) |
| Perianal disease, n (%) | 30 (25.4) |
| Smoking habits, n (%) | |
| Yes | 36 (30.5) |
| Not | 59 (50) |
| Ex | 23 (19.5) |
| Familial history, n (%) | 23 (19.5) |
| Need for steroids at diagnosis, n (%) | 60 (50.8) |
| Previous surgery, n (%) | 58 (49.2) |
| Previous thiopurines exposure, n (%) | 47 (39.8) |
| Extra-intestinal manifestations, n (%) | 48 (40.7) |
| Biologic, n (%) | |
| IFX | 10 (8.5) |
| ADA | 75 (63.6) |
| VDZ | 18 (15.3) |
| UST | 15 (12.7) |
| Combination therapy, n (%) | 6 (5.1) |
Combination therapy: the concomitant association of anti-TNF alpha and immunomodulators such as azathioprine or 6-mercaptopurine.
ADA, adalimumab; SD, standard deviation; IFX, Infliximab; n, number; TNF, tumor necrosis factor; UST, ustekinumab; VDZ, vedolizumab.